Someone else already paid for the growth: management describes an outside party bearing the cost, risk, or work that exp
The model's full reasoning — Q2 2018 call → YESThe question is about whether management describes an outside party already bearing the cost, risk, or work of expanding the company's business, with the effort real and underway now, but the resultin...YES The transcript shows management describing real, ongoing outside efforts by franchisees and partners already bearing the cost, risk, and work of expansion. Franchisees are actively spending their own capital to open units (e.g., 482 net new units YTD vs. 317 last year; KFC opening nearly 200 2Q units; Pizza Hut 6% net new unit growth; Taco Bell 9 international units), with the company 97% franchised and on track for 98%. These efforts are already in motion and contributing to current results, while management highlights acceleration and future ramp (e.g.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| IMAX | IMAX Corporation | Q2 2023 | 2023-07-26 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| VVV | Valvoline Inc. | Q1 2022 | 2022-02-09 | C+ |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PCRX | Pacira BioSciences, Inc. | Q4 2017 | 2018-02-28 | C |
| INST | Instructure's | Q4 2017 | 2018-02-12 | B+ |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| MITK | Mitek Systems, Inc. | Q4 2017 | 2017-11-07 | C+ |
| SNA | Snap-on Incorporated | Q3 2017 | 2017-10-19 | B |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| MGNX | MacroGenics, Inc. | Q3 2016 | 2016-11-02 | D |
| CRIS | Curis, Inc. | Q1 2016 | 2016-05-09 | C |
INST · Q4 2017 → YESThe question is about whether management describes an outside party already bearing the cost, risk, or work of expanding the company's business, with the effort real and underway now, but the resultin...YES The transcript shows management describing the Paychex partnership as a white-label reseller arrangement where Paychex is already bearing the cost, risk, and work of expanding Instructure’s business by offering Bridge Learn to its 0.5 million customers (6 million users) using its own salesforce and customer base — a real, underway effort since the partnership was entered into and integration is already in progress. Management explicitly states Paychex owns the customers and will sell the product, while Instructure is only powering the backend, and the resulting revenue is still mostly ahead (they are optimistic about significant success by year-end). This matches 100% of the required criteria.
PLAB · Q2 2017 → YESThe question is about whether management describes an outside party already bearing the cost, risk, or work of expanding the company's business, with the effort real and underway now, but the resultin...YES The transcript shows management describing the DNP JV as an outside party already bearing the bulk of the expansion costs and risks for the new China facility (the $160 million Xiamen site, previously announced as a company-led greenfield build last August). Peter Kirlin notes they will "utilize all cash held in Taiwan and greater reduced to risk of ramping of our new factory in China," while Sean Smith confirms they are "sharing that total investment of 160 million as we in essence have a 50-50 partnership, however we will consolidate it" and will "share equitably the startup cost.
IONS · Q1 2017 → YESThe question is about whether management describes an outside party already bearing the cost, risk, or work of expanding the company's business, with the effort real and underway now, but the resultin...YES Management describes the Novartis collaboration as an outside party (Novartis) already bearing the cost, risk, and work of expanding the business: Novartis is responsible for globally developing and commercially launching the drugs and paying for the outcome studies (assuming option exercise), while Akcea has no obligation to fund them. The effort is real and underway now with the Phase IIb study initiated by Akcea and $175 million already received, but the resulting large-scale commercialization and outcome data are still mostly ahead.